M.D., CEO, AvidBiotics
David Martin a founder and CEO of Eos Biotechnology, which merged with Protein Design Labs. Previously, he has been senior vice-president of R&D at Genentech, executive vice-president of R&D at DuPont Merck, and president of Chiron Therapeutics. He currently serves as lead director of the boards of Varian Medical Systems and Cubist Pharmaceuticals, and is a member of the executive committee of BayBio. Prior to Genentech, he was professor of medicine and biochemistry at the University of California, San Francisco and investigator, Howard Hughes Medical Institute. He attended the Massachusetts Institute of Technology, and received his M.D. from Duke University.
MicAbody™ Proteins Engage NK- and T-Cells
Tumor-specific antibodies engineered to tightly bind NKG2D immunoreceptors can redirect and activate innate and adaptive immunity. Because of their extraordinary avidity for NKG2D, MicAbody proteins decorate NK- and T-cells with targeting antibodies and do not require gene therapy or cell engraftment. This bispecific MicAbody platform offers multiple immunotherapeutic strategies.